# Radionetics Oncology

**Canonical:** https://apis.io/providers/radionetics-oncology/  
**Website:** https://radionetics.com  
**APIs profiled:** 0

Radionetics Oncology is a clinical-stage biotechnology company developing precision radiopharmaceutical treatments for cancer. The company designs small-molecule radioligands that target G-protein-coupled receptors (GPCRs) to selectively deliver targeted radiation therapy to solid tumors, including breast and lung cancer, combining GPCR biology expertise with medicinal chemistry. Radionetics entered a strategic agreement with Eli Lilly in 2024. It was surfaced as a portfolio company of DCVC and added to the API Evangelist network; the company publishes no public developer, API, or technical-integration surface at this time.

## Kin Score — 7.9 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 7.9).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 10.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biotechnology, Pharmaceuticals, Radiopharmaceuticals, Oncology, Precision Medicine, Life Sciences, Healthcare

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/radionetics-oncology/). Scores are computed from the provider's own public artifacts under a published rubric.